© 2000 by Society
© 2000 by the Society forNeuro-Oncology
Analysis of genomic rearrangements associated with EGFRvIII expressionsuggests involvement of Alu repeat elements
Department of Laboratory Medicine and Pathology and Tumor BiologyProgram, Mayo Clinic and Foundation, Rochester, MN 55905
2 Address correspondence and reprint requests to C. David James, Mayo Clinic,200 First St., S.W., Hilton Bldg. Rm. 820-D, Rochester, MN 55905.
| Abstract |
|---|
We have developed a polymerase chain reaction (PCR)-based strategy for thesynthesis and analysis of rearranged epidermal growth factor receptor(EGFR) fragments associated with the vIII mutant receptor expressedin glioblastomas with EGFR amplification. The sequencing of aberranttumor fragments showed that intragenic deletion rearrangements consistentlyinvolve an approximately 600-bp region in intron 7 of EGFR andseveral rearrangement sites interspersed throughout the large (>100 kb)first intron of this gene. Examination of the intron 7 breakpoint regionrevealed an Alu repeat element, and all intron 7 rearrangement sites werelocated within or downstream of this repeat sequence. Analysis of intron 1 forsimilar sequences resulted in the identification of 11 sites containing>80% homology with parts of the Alu element in intron 7. Reversetranscriptase-PCR and/or Western analysis of the tumors showed the presence ofEGFRvIII cDNAs and/or proteins, respectively, in all cases for which arearranged genomic fragment was generated by long-range PCR. Collectively,these data suggest that EGFR rearrangements, associated with thesynthesis of the most common EGFR mutant, are mediated by a specific sequenceelement.
Received March 8, 2000; Accepted March 30, 2000
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. H. Huang, A. M. Xu, and F. M. White Oncogenic EGFR Signaling Networks in Glioma Sci. Signal., September 8, 2009; 2(87): re6 - re6. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. van den Bent, A. A. Brandes, R. Rampling, M. C.M. Kouwenhoven, J. M. Kros, A. F. Carpentier, P. M. Clement, M. Frenay, M. Campone, J.-F. Baurain, et al. Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034 J. Clin. Oncol., March 10, 2009; 27(8): 1268 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Gazdar and J. D. Minna Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops Cancer Prevention Research, August 1, 2008; 1(3): 156 - 160. [Full Text] [PDF] |
||||
![]() |
P. J. French, J. Peeters, S. Horsman, E. Duijm, I. Siccama, M. J. van den Bent, T. M. Luider, J. M. Kros, P. van der Spek, and P. A. Sillevis Smitt Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays Cancer Res., June 15, 2007; 67(12): 5635 - 5642. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-K. Wong, Y. T.M. Tsang, Y.-M. Chang, J. Su, A. M. Di Francesco, D. Meco, R. Riccardi, L. Perlaky, R. C. Dauser, A. Adesina, et al. Genome-Wide Allelic Imbalance Analysis of Pediatric Gliomas by Single Nucleotide Polymorphic Allele Array Cancer Res., December 1, 2006; 66(23): 11172 - 11178. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors PNAS, May 16, 2006; 103(20): 7817 - 7822. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Choe, J. K. Park, L. Jouben-Steele, T. J. Kremen, L. M. Liau, H. V. Vinters, T. F. Cloughesy, and P. S. Mischel Active Matrix Metalloproteinase 9 Expression Is Associated with Primary Glioblastoma Subtype Clin. Cancer Res., September 1, 2002; 8(9): 2894 - 2901. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Eley, J. L. Reiter, A. Pandita, S. Park, R. B. Jenkins, N. J. Maihle, and C. D. James A chromosomal region 7p11.2 transcript map: Its development andapplication to the study of EGFR amplicons in glioblastoma Neuro Oncology, April 1, 2002; 4(2): 86 - 94. [Abstract] [PDF] |
||||






